Trial · NCT04462809
Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma
NCT04462809, Phase 2, Unknown, Hospices Civils de Lyon
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma. Trials, record NCT04462809. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04462809
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma
- NCT number
- NCT04462809
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Hospices Civils de Lyon
- Conditions
- Advanced Malignant Pleural or Peritoneal Mesothelioma
- Interventions
- Talazoparib
- First posted
- 2020-07-08
- Last updated
- 2020-07-09
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Non-progression proportion | 6 month after starting talazoparib | The non-progression proportion is defined as the proportion of patients free of progression 6 months after talazoparib start. Disease progression will be based on (i) tumor assessment made by the investigators according to the RECIST 1.1 criteria and/or, ii) non-equivocal clinical symptom of disease progression according to the investigator; (iii) death related to disease progression. |
| Secondary | Progression free survival | Patients will be followed until the end of the study for collect date on progression and date of eventually death : .25 month for the latest enrolled patient to 49 months for the first one.) | The Progression-Free Survival (PFS) is defined as the time from inclusion to (1) first documented disease progression or death related to disease progression, whichever occurs first or, (2) end of follow-up. |
| Secondary | Progression free-survival based on RECIST 1.1 criteria | Patients will be followed until the end of the study for collect date on progression and date of eventually death : .25 month for the latest enrolled patient to 49 months for the first one. | The Progression-Free Survival (PFS) is defined as the time from inclusion to first documented disease progression or death related to disease progression, whichever occurs first or, end of follow-up. Disease progression will be based on tumor assessment made by the investigators according to the RECIST 1.1 criteria and/or, non-equivocal clinical symptom of disease progression according to the investigator, and/or death related to disease progression. |
| Secondary | Progression free-survival based on mRECIST criteria | Patients will be followed until the end of the study for collect date on progression and date of eventually death : .25 month for the latest enrolled patient to 49 months for the first one. | The Progression-Free Survival (PFS) is defined as the time from inclusion to first documented disease progression or death related to disease progression, whichever occurs first or, end of follow-up. Disease progression will be based on tumor assessment made by the investigators according to the mRECIST criteria and/or, non-equivocal clinical symptom of disease progression according to the investigator, and/or death related to disease progression. |
| Secondary | Overall Survival | Patients will be followed until the end of the study for collect date on progression and date of eventually death : .25 month for the latest enrolled patient to 49 months for the first one. | The Overall Survival (OS) will be estimated from the date of inclusion to the date of death or to the end of follow-up. |
| Secondary | Safety, treatment-related adverse events | 6 weeks after the last experimental treatment for the latest enrolled patient | treatment-related adverse events are defined as the nature, number and grade of adverse events observed throughout the study and assessed using NCI-CTCAE v.5.0 criteria. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04462809
GET https://conductscience.org/api/trials/v1/NCT04462809/registered